Analyst Price Targets — DNA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 25, 2025 11:43 am | — | BTIG | $9.00 | $12.05 | TheFly | Ginkgo Bioworks price target raised to $9 from $6 at BTIG |
| August 23, 2024 7:02 am | Mark Massaro | BTIG | $7.00 | $8.30 | TheFly | Ginkgo Bioworks price target lowered to $7 from $8 at BTIG |
| November 29, 2022 4:38 am | — | Berenberg Bank | $6.00 | $1.84 | Benzinga | Berenberg Initiates Coverage On Ginkgo Bioworks Holdings with Buy Rating, Announces Price Target of $6 |
| August 16, 2022 9:33 am | — | BTIG | $6.00 | $3.74 | Benzinga | BTIG Maintains Buy on Ginkgo Bioworks Holdings, Raises Price Target to $6 |
| June 16, 2022 9:07 am | — | Jefferies | $4.35 | $2.59 | Benzinga | Jefferies Maintains Buy on Ginkgo Bioworks Holdings, Lowers Price Target to $4.35 |
| March 3, 2022 12:00 am | Steven Mah | Cowen & Co. | $12.00 | $3.86 | Pulse 2.0 | Ginkgo Bioworks, Inc. (DNA) Stock: $12 Price Target And Outperform Rating |
Latest News for DNA
Ginkgo Bioworks reported Q4 revenues of $33 million, down 24% year-over-year, and missing estimates by over $4 million. Cell Engineering, expected to drive growth, delivered just $125 million in 2025 revenue, far below the original $1.1 billion SPAC projection. Management is pivoting by selling the Biosecurity segment, retaining only a minority stake in the new private entity.
BOSTON, March 2, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to transition their benchwork to Ginkgo's autonomous lab infrastructure directly through a web browser.
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript
Ginkgo Bioworks (NYSE: DNA) shares are down following the company's fourth-quarter and full-year 2025 financial report.
Ginkgo provides an update on its fourth quarter financial results BOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DNA.
U.S. House Trading
No House trades found for DNA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.